Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash from Financing Activities (2016 - 2025)

Northwest Biotherapeutics' Cash from Financing Activities history spans 16 years, with the latest figure at $13.6 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $13.6 million for Q4 2025, down 14.77% from a year ago — trailing twelve months through Dec 2025 was $49.3 million (down 13.13% YoY), and the annual figure for FY2025 was $49.3 million, down 13.13%.
  • Cash from Financing Activities for Q4 2025 was $13.6 million at Northwest Biotherapeutics, up from $11.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $23.7 million in Q4 2021 to a low of $3.9 million in Q1 2022.
  • The 5-year median for Cash from Financing Activities is $11.9 million (2024), against an average of $12.4 million.
  • The sharpest move saw Cash from Financing Activities plummeted 63.71% in 2021, then skyrocketed 220.97% in 2023.
  • Year by year, Cash from Financing Activities stood at $23.7 million in 2021, then crashed by 52.04% to $11.4 million in 2022, then increased by 26.99% to $14.4 million in 2023, then grew by 10.59% to $15.9 million in 2024, then fell by 14.77% to $13.6 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $13.6 million, $11.6 million, and $12.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.